Second megaround of ‘19 to help Passage broaden rare CNS disease pipeline

The gene therapy team and scientific foundation behind Passage Bio continue to attract investors, as the company said Wednesday it had raised $110 million in a series B round led by Access Biotechnology.

The investment comes less than seven months after the February launch of Passage Bio Inc. (Philadelphia, Pa.) with $115.5 million in series A funding and licenses to five gene therapies from the lab of gene therapy pioneer James Wilson at the University of Pennsylvania. Wilson is the company’s chief scientific adviser and a co-founder...